Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling

Oncogene

Volumn 33, Issue 30, 2014, Pages 3970-3979

  Kumar, S ^a   Pan, C C ^a   Bloodworth, J C ^a   Nixon, A B ^b   Theuer, C ^c   Hoyt, D G ^a   Lee, N Y ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c TRACON Pharmaceuticals   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 9; CYTOCHROME C; ENDOGLIN; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY TRACON105; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SOLUBLE ENDOGLIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL DISRUPTION; CELL GROWTH; CELL INTERACTION; CELL JUNCTION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLID TUMOR; STEADY STATE; STRESS FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL MEMBRANE; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 14; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904995268     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.386     Document Type: Article

References (45)

1. Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359-1370
2. Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F et al. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res 2011; 31: 2651-2655
3. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009; 125: 1446-1453
4. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H et al. Anti-Tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008; 122: 2266-2273 (Pubitemid 351542330)
5. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-Angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 2006; 29: 1087-1094
6. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ et al. Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937 (Pubitemid 351551101)
7. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-1537
8. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19
9. Düwel A, Eleno N, Jerkic M, Arevalo M, Bolaños JP, Bernabeu C et al. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol 2007; 28: 1-8 (Pubitemid 46012460)
10. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. Embo J 2004; 23: 4018-4028 (Pubitemid 39472423)
11. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1 in endothelial cells. Blood 2007; 109: 1953-1961 (Pubitemid 46348192)
12. Tsirakis G, Pappa CA, Spanoudakis M, Chochlakis D, Alegakis A, Psarakis FE et al. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Intern Med 2012; 23: 368-373
13. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010; 70: 4141-4150
14. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan Domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011; 286: 30034-30046
15. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012; 18: 4820-4829
16. Daly AC, Randall RA, Hill CS. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 2008; 28: 6889-6902
17. Lee BH, Chen W, Stippec S, Cobb MH. Biological cross-Talk between WNK1 and the transforming growth factor beta-Smad signaling pathway. J Biol Chem 2007; 282: 17985-17996 (Pubitemid 47100246)
18. Pan CC, Bloodworth JC, Mythreye K, Lee NY. Endoglin inhibits ERK-induced c-Myc and cyclin D1 expression to impede endothelial cell proliferation. Biochem Biophys Res Commun 2012; 424: 620-623
19. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 2005; 280: 27800-27808 (Pubitemid 41076895)
20. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005 (Pubitemid 44343543)
21. Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, Recio-Rodríguez JI, Sánchez-Rodríguez A, Ló pez-Novoa JM et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010; 8: 86
22. Pérez-Gómez E, Del Castillo G, Juan Francisco S, Ló pez-Novoa JM, Bernabéu C, Quintanilla M. The role of the TGF-beta coreceptor endoglin in cancer. ScientificWorldJournal 2010; 10: 2367-2384
23. Lopez-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010; 299: H959-H974
24. Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SR. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med 2008; 102: 845-851
25. Cherney RJ, King BW, Gilmore JL, Liu RQ, Covington MB, Duan JJ et al. Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg Med Chem Lett 2006; 16: 1028-1031 (Pubitemid 43059872)
26. Covington MD, Burghardt RC, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 2006; 290: F43-F51
27. Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA et al. Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 2000; 19: P 5926-5935 (Pubitemid 32005374)
28. Ehrlich M, Horbelt D, Marom B, Knaus P, Henis YI. Homomeric and heteromeric complexes among TGF-beta and BMP receptors and their roles in signaling. Cell Signal 2011; 23: 1424-1432
29. Marom B, Heining E, Knaus P, Henis YI. Formation of stable homomeric and transient heteromeric bone morphogenetic protein (BMP) receptor complexes regulates Smad protein signaling. J Biol Chem 2011; 286: 19287-19296
30. Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem 2011; 286: 10495-10504
31. Willis BC, Borok Z. TGF-beta-induced EMT: Mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L525-L534 (Pubitemid 47358808)
32. Lee NY, Ray B, How T, Blobe GC. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 2008; 283: 32527-32533
33. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabéu C et al. Endoglin controls cell migration and composition of focal adhesions: Function of the cytosolic domain. J Biol Chem 2004; 279: 27440-27449 (Pubitemid 38812583)
34. Lee NY, Blobe GC. The interaction of endoglin with beta-Arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem 2007; 282: 21507-21517 (Pubitemid 47099970)
35. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR et al. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 2013; 210: 563-579
36. Park S, Dimaio TA, Liu W, Wang S, Sorenson CM, Sheibani N. Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-beta signaling pathways. J Cell Sci 2013; 126(Pt 6): 1392-1405
37. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274: 584-594
38. Santibanez JF, Pé rez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, Malumbres M et al. The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis 2010; 31: 2145-2154
39. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CP, Bernabéu C. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem 2004; 279: 32858-32868 (Pubitemid 39014746)
40. Meng Q, Lux A, Holloschi A, Li J, Hughes JM, Foerg T et al. Identification of Tctex2beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. J Biol Chem 2006; 281: 37069-37080 (Pubitemid 46042177)
41. Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One 2012; 7: E50920
42. Lee NY, Haney JC, Sogani J, Blobe GC. Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J 2009; 23: 3712-3721
43. Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC. Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol Biol Cell 2012; 23: 2412-2423
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression Data using real-Time quantitative PCR and the 2(-DDCT) Method. Methods 2001; 25: 402-408 (Pubitemid 34164012)
45. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P et al. S100A7 Enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012; 72: 604-615.